RBC Capital analyst Shagun Singh lowered the firm’s price target on Johnson & Johnson to $175 from $181 but keeps an Outperform rating on the shares. The company delivered in-line sales and EPS beat for Q1 while its underlying utilization trends appeared positive, with stable to improving stacked 2-year growth implying that its fundamentals are strong, the analyst tells investors in a research note. RBC adds however that its price target cut aligns the stock better with its peers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- JNJ Earnings: Johnson & Johnson’s Q1 Earnings Beat Estimates
- Options Volatility and Implied Earnings Moves Today, April 16, 2024
- Johnson & Johnson sees ‘slightly stronger’ sales in Innovative Medicine in 1H24
- Johnson & Johnson raises quarterly dividend 4.2% to $1.24 from $1.19 per share
- Johnson & Johnson revises FY24 adjusted EPS to $10.60-$10.75 from $10.55-$10.75